<DOC>
	<DOC>NCT00540657</DOC>
	<brief_summary>The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease</brief_summary>
	<brief_title>A Phase II Study of CCX282-B in Patients With Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Key Male or female, between 18 and 75 years of age Established diagnosis of celiac disease Subject has been following a strict glutenfree diet for at least 24 months Key History of any infection requiring intravenous antibiotics, a serious local infection, systemic infection, or gastrointestinal infection within 12 weeks of randomization Use of any immunosuppressants, TNF inhibitors, or natalizumab during the 12 weeks prior to study randomization Use of steroids during the 4 weeks prior to study randomization Receipt of an experimental treatment for any disease within 4 weeks prior to randomization Known IgEmediated atopy or allergy or anaphylactic reactions to gluten The subject suffers from a condition that carries a risk at endoscopy or is on anticoagulant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>